The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2019 | Current affairs: opinion on quizartinib approval status in AML
Mark Levis, MD, PhD, from the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the current status of quizartinib monotherapy for FLT3+ relapsed/refractory acute myeloid leukemia (AML) following the results of the QuANTUM-R trial (NCT02039726). He also expresses his excitement about the devlopment of the QuANTUM-First trial (NCT02668653). This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
